Caris Life Sciences Collaborates with Merck KGaA to Discover and Develop Antibody Drug Conjugate for Cancer Treatment
Shots:
- Caris & Merck KGaA have signed a multi-year strategic collaboration for the discovery of FIC targets & expedite the development of ADCs for cancer treatment
- Under the collaboration, Caris will receive upfront & funding for research plus a total of $1.4B as discovery, development, regulatory & sales-based milestones as well as tiered royalties while Merck KGaA gains an exclusive worldwide license for developing, manufacturing & commercializing the candidates
- Merck KGaA will handle preclinical & clinical development as well as commercialization of the targets that will be discovered by Caris' molecular profiling business along with ADAPT Biotargeting platform, patient tissue repository as well as AI & ML capabilities
Ref: Caris Life Sciences | Image: Caris Life Sciences
Related News:- AstraZeneca Acquires Fusion Pharmaceuticals for ~$2.4B to Development Radioconjugates for Cancer Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
